Clinical Trial Update: Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of Alirocumab added to lipid-modifying therapy in patients with heterozygous familial hypercholesterolemia not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heterozygous Familial Hypercholesterolemia
• Hypercholesterolemia

Drugs mentioned

• alirocumab (alirocumab)

Snippet

Sponsor: Sanofi | Conditions: Hypercholesterolemia | Phase 3 | Status: COMPLETED | Results posted: 2015-11-04